Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor added to induction chemotherapy in older adults with AML or high-risk MDS
NL-OMON44963Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of selinexor in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 arms), sponsored by HOVON. Primary endpoints: Dose-limiting toxicity and Complete remission rate. Started Jun 2017; status: recruiting.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON44963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44963.